Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age
Objective: To evaluate a dose-dependent reduction in blood pressure (BP) and overall safety of valsartan in hypertensive children. Method: In a multicenter, randomized, double-blind, parallel-group study, 75 patients with a documented history of hypertension were randomized (2 : 1 : 2) to receive va...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2013
|
| In: |
Journal of hypertension
Year: 2013, Jahrgang: 31, Heft: 5, Pages: 993-1000 |
| ISSN: | 1473-5598 |
| DOI: | 10.1097/HJH.0b013e32835f5721 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/HJH.0b013e32835f5721 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/jhypertension/Fulltext/2013/05000/Efficacy_and_safety_of_valsartan_in_hypertensive.23.aspx 
|
| Verfasserangaben: | Franz Schaefer, Rosanna Coppo, Arvind Bagga, Prabha Senguttuvan, Rolf Schlosshauer, Ying Zhang, and Mahomed Kadwa |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 178832448X | ||
| 003 | DE-627 | ||
| 005 | 20240415193324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220202s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HJH.0b013e32835f5721 |2 doi | |
| 035 | |a (DE-627)178832448X | ||
| 035 | |a (DE-599)KXP178832448X | ||
| 035 | |a (OCoLC)1341439554 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schaefer, Franz |d 1961- |e VerfasserIn |0 (DE-588)1023365383 |0 (DE-627)718365577 |0 (DE-576)366705598 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age |c Franz Schaefer, Rosanna Coppo, Arvind Bagga, Prabha Senguttuvan, Rolf Schlosshauer, Ying Zhang, and Mahomed Kadwa |
| 246 | 3 | 3 | |a Efficacy and safety of valsartan in hypertensive children six months to five years of age |
| 264 | 1 | |c 2013 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.02.2022 | ||
| 520 | |a Objective: To evaluate a dose-dependent reduction in blood pressure (BP) and overall safety of valsartan in hypertensive children. Method: In a multicenter, randomized, double-blind, parallel-group study, 75 patients with a documented history of hypertension were randomized (2 : 1 : 2) to receive valsartan (0.25, 1 or 4 mg/kg per day) for 6 weeks, then rerandomized (1 : 1) to receive placebo or valsartan for 2 weeks. This followed the 18-week extension study in which all patients received open-label valsartan (1 mg/kg initial dose, titratable up to 4 mg/kg). The primary endpoint was the slope analysis of the dose-response curve for mean sitting SBP (MSSBP) derived through MSSBP reduction over the first 6 weeks. Safety was assessed in terms of adverse events and serious adverse events (SAEs). Results: At Week 6, significant reductions in MSSBP (P < 0.05) from baseline were observed for all three valsartan doses. Greater reductions were observed with the medium and high doses, although the dose-response trend was not statistically significant (P = 0.099). At Week 8, a greater increase in BP was observed in patients who switched from valsartan to placebo; the difference was not significant. At the extension endpoint, MSSBP was comparable to that observed at Week 6 of the core study. Overall, valsartan was well tolerated with no dose-dependent increase in adverse events during the dose-ranging period (Week 0-6) and a comparable incidence of adverse events to placebo during the placebo withdrawal period (Week 7-8). Conclusion: Although a dose-response trend was observed, statistical significance was not achieved during the dose ranging (primary endpoint) or the placebo-withdrawal periods of the study. However, valsartan demonstrated significant reductions in BP compared with baseline and provided consistent reductions over 26 weeks. | ||
| 700 | 1 | |a Coppo, Rosanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bagga, Arvind |e VerfasserIn |4 aut | |
| 700 | 1 | |a Senguttuvan, Prabha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlosshauer, Rolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhang, Ying |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kadwa, Mahomed |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hypertension |d London : Lippincott, Williams & Wilkins, 1983 |g 31(2013), 5, Seite 993-1000 |h Online-Ressource |w (DE-627)320581373 |w (DE-600)2017684-3 |w (DE-576)091014018 |x 1473-5598 |7 nnas |a Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age |
| 773 | 1 | 8 | |g volume:31 |g year:2013 |g number:5 |g pages:993-1000 |g extent:8 |a Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age |
| 856 | 4 | 0 | |u https://doi.org/10.1097/HJH.0b013e32835f5721 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/jhypertension/Fulltext/2013/05000/Efficacy_and_safety_of_valsartan_in_hypertensive.23.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220202 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 1023365383 |a Schaefer, Franz |m 1023365383:Schaefer, Franz |d 910000 |d 910500 |d 50000 |e 910000PS1023365383 |e 910500PS1023365383 |e 50000PS1023365383 |k 0/910000/ |k 1/910000/910500/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN178832448X |e 4049875101 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1097/HJH.0b013e32835f5721"],"eki":["178832448X"]},"recId":"178832448X","origin":[{"dateIssuedDisp":"2013","dateIssuedKey":"2013"}],"name":{"displayForm":["Franz Schaefer, Rosanna Coppo, Arvind Bagga, Prabha Senguttuvan, Rolf Schlosshauer, Ying Zhang, and Mahomed Kadwa"]},"language":["eng"],"titleAlt":[{"title":"Efficacy and safety of valsartan in hypertensive children six months to five years of age"}],"note":["Gesehen am 02.02.2022"],"person":[{"family":"Schaefer","role":"aut","display":"Schaefer, Franz","given":"Franz"},{"given":"Rosanna","display":"Coppo, Rosanna","family":"Coppo","role":"aut"},{"family":"Bagga","role":"aut","display":"Bagga, Arvind","given":"Arvind"},{"display":"Senguttuvan, Prabha","family":"Senguttuvan","role":"aut","given":"Prabha"},{"given":"Rolf","display":"Schlosshauer, Rolf","role":"aut","family":"Schlosshauer"},{"given":"Ying","display":"Zhang, Ying","family":"Zhang","role":"aut"},{"display":"Kadwa, Mahomed","role":"aut","family":"Kadwa","given":"Mahomed"}],"relHost":[{"note":["Gesehen am 27.11.20","Ungezählte Beil.: Suppl"],"pubHistory":["1.1983 -"],"language":["eng"],"disp":"Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of ageJournal of hypertension","origin":[{"dateIssuedKey":"1983","publisherPlace":"London","dateIssuedDisp":"1983-","publisher":"Lippincott, Williams & Wilkins"}],"recId":"320581373","id":{"zdb":["2017684-3"],"eki":["320581373"],"issn":["1473-5598"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Journal of hypertension","subtitle":"official journal of International Society of Hypertension, European Society of Hypertension","title":"Journal of hypertension"}],"part":{"extent":"8","year":"2013","pages":"993-1000","issue":"5","text":"31(2013), 5, Seite 993-1000","volume":"31"}}],"title":[{"title_sort":"Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age","title":"Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age"}],"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a SCHAEFERFREFFICACYAN2013 | ||